Silver Book Fact

One economic model predicts that if type 1 and type 2 diabetics had begun Captopril (a drug that controls blood pressure and delays the onset of kidney failure) treatment in 1995, the aggregate health care cost savings in 1999 would have been $189 million and in 2004 would have been $475 million-a present value cumulative cost savings of $2.4 billion for those 10 years.

Rodby R, Firth L, Lewis E. An Economic Analysis of Captopril in the Treatment of Diabetic Nephropathy. Diabetes Care. 1996; 19(10): 1051-61. http://care.diabetesjournals.org/cgi/content/abstract/19/10/1051

Reference

Title
An Economic Analysis of Captopril in the Treatment of Diabetic Nephropathy
Publication
Diabetes Care
Publication Date
1996
Authors
Rodby R, Firth L, Lewis E
Volume & Issue
Volume 19, Issue 10
Pages
1051-61
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • For diabetes patients aged 55 and older, medical nutrition therapy was found to reduce the use of hospital services by 9.5% and physicians services by 23.5%.  
  • Medicines Reduce Complications of Diabetes: Diabetes patients treated with medicines are less likely to develop other health problems  
  • Economics of DR Treatment
    Laser treatment plus a VEGF inhibitor achieved an incremental cost-effectiveness ratio of $12,410 per quality adjusted life year in patients with DME.  
  • In a community-based pharmaceutical care services program for 194 participants in 2001, days of sick time decreased at each interval (each year for 1-5 years) for one employer, with estimated…  
  • A study by the Diabetes Prevention Program found that the use of the drug metformin by high-risk patients reduced the risk of development of type 2 diabetes by 31%.